Guru P. Sonpavde MD
Genitourinary Oncology Director, Christopher K. Glanz Chair for Bladder Cancer Research, Assistant Director Phase I Clinical Research Unit, AdventHealth Cancer Institute, Orlando, FloridaDr. Guru Sonpavde, MD, is the Genitourinary Oncology Director at the AdventHealth Cancer Institute and the Christopher K. Glanz Chair for Bladder Cancer Research. He completed his fellowship in medical oncology and hematology at Indiana University. He leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to treat urological cancers, particularly bladder cancer. He is the national or international principal investigator on multiple clinical trials for bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.
Disclosures
Dr. Sonpavde reports the following:
-
Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV
-
Research Support: Sanofi (iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric, Kure it, NCI (R21)
- Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid)
- Data safety monitoring committee: Mereo
- Employment: Spouse employed by Myriad
- Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence
- Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS)
Recent Contributions to PracticeUpdate:
- ASCO: Outcomes of Patients With Metastatic Urothelial Carcinoma Following Discontinuation of Enfortumab-Vedotin
- ASCO: Adjuvant Chemotherapy Plus Novel Therapies for Muscle-Invasive Bladder Cancer
- Pattern of Adverse Events With New Immuno-Oncology Agents: Implications for Monitoring
- AACR: Combination Checkpoint Inhibitor and Chemotherapy for Advanced Urothelial Carcinoma
- Integrating Immuno-Oncology and Targeted Therapy for Bladder Cancer in Practice
- FGFR Inhibitors in Bladder Cancer
- Erdafitinib in Urothelial Carcinoma
- Role of Checkpoint Inhibition for Localized Bladder Cancer
- Prognostic Model for Patients With Metastatic Urothelial Cancer Receiving Checkpoint Inhibitors
- Treatment Sequencing of Checkpoint Inhibitors and Chemotherapy for Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer